Update on lung cancer from the annual meeting of the American society of clinical oncology 2012

被引：0
作者：
Sacha I. Rothschild
Oliver Gautschi
机构：
[1] Department Internal Medicine Medical Oncology, University Hospital Basel, 4031 Basel
[2] Medical Oncology, Luzerner Kantonsspital, Lucerne
来源：
memo - Magazine of European Medical Oncology | 2012年 / 5卷 / 4期
关键词：
ASCO; Chemotherapy; Maintenance; Nonsmall cell lung cancer;
D O I：
10.1007/s12254-012-0050-z
中图分类号：
学科分类号：
摘要：
The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, Illinois (USA) from June 1-5, 2012. In the lung cancer track, several hundreds of abstracts were presented. The following article will give an overview on some interesting and relevant abstracts. Beside new drugs, the role of biomarker, and maintenance therapy, we will also discuss issues on early-stage disease. © 2012 Springer-Verlag Wien.
引用
收藏
页码：253 / 258
页数：5
相关论文
共 35 条
  • [1] Senan S., Verstegen N.E., Palma D., Rodrigues G., Lagerwaard F.J., Van Der Elst A., Et al., Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis, J Clin Oncol., 30, SUPPL., (2012)
  • [2] Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group, J Clin Oncol., 26, 21, pp. 3552-3559, (2008)
  • [3] Shepherd F.A., Bourredjem A., Brambilla E., Domerg C., Douillard J.-Y., Filipits M., Et al., Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study, J Clin Oncol., 30, SUPPL., (2012)
  • [4] Yamamoto S., Tsjujino K., Ando M., Kawaguchi T., Kubo A., Isa S., Et al., Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature, J Clin Oncol., 30, SUPPL., (2012)
  • [5] Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., Et al., Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J Clin Oncol., 17, 9, pp. 2692-2699
  • [6] Zatloukal P., Petruzelka L., Zemanova M., Havel L., Janku F., Judas L., Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study, Lung Cancer., 46, 1, pp. 87-98, (2004)
  • [7] Huber R.M., Engel-Riedel W., Kollmeier J., Andreas S., Staar S., Klautke G., Et al., GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study, J Clin Oncol., 30, SUPPL., (2012)
  • [8] Paz-Ares L., De Marinis F., Dediu M., Thomas M., Pujol J.L., Bidoli P., Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial, Lancet Oncol, 13, 3, pp. 247-255, (2012)
  • [9] Paz-Ares L., De Marinis F., Dediu M., Thomas M., Pujol J.-L., Bidoli P., Et al., PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC), J Clin Oncol., 30, SUPPL., (2012)
  • [10] Jc-H Y., Schuler M.H., Yamamoto N., O'Byrne K.J., Hirsh V., Mok T., Et al., LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations, J Clin Oncol., 30, SUPPL., (2012)
1234